Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | PNP | P00491 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xanthopterin SCHEMBL2489021 | 0.68 | ALDH1A1 (0.53) | MAPTPNPCYP3A4BLMALDH1A1 | |
| SCHEMBL16247077 | 0.67 | ALDH1A1 (0.45) | MAPTPNPCYP3A4BLMALDH1A1 | |
| Guanine SCHEMBL342789 | 0.67 | ADORA3 (0.62) | PNPALDH1A1HPGDUSP2TP53 | |
| SCHEMBL11465960 | 0.65 | MAPT (0.39) | MAPTPNPXDH | |
| Guanine SCHEMBL28026510 | 0.64 | ADORA3 (0.59) | PNPALDH1A1HPGDUSP2TP53 | |
| Leucopterin SCHEMBL12948394 | 0.63 | PNP (0.43) | MAPTPNPCYP3A4BLMALDH1A1 | |
| SCHEMBL3180702 | 0.61 | PNP (0.37) | MAPTPNPCYP3A4BLMTP53 | |
| Pterine SCHEMBL64321 | 0.60 | ALDH1A1 (0.41) | MAPTPNPCYP3A4BLMALDH1A1 | |
| SCHEMBL1980402 | 0.60 | ALDH1A1 (0.37) | MAPTPNPCYP3A4BLMALDH1A1 | |
| SCHEMBL460884 | 0.60 | PNP (0.39) | MAPTPNPCYP3A4BLMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091500-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2021-08-17 | — | — | US | disclosed |
| US-10676483-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-06-09 | — | — | US | disclosed |
| EP-2310014-B1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | UNIV HOLY GHOST DUQUESNE (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20200017521-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2020-01-16 | — | — | US | disclosed |
| US-10464944-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-11-05 | — | — | US | disclosed |
| US-10414777-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and method of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-09-17 | — | — | US | disclosed |
| US-9987283-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2018-06-05 | — | — | US | disclosed |
| US-20180127434-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHOD OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2018-05-10 | — | — | US | disclosed |
| US-9802955-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170246170-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2017-08-31 | — | — | US | disclosed |
| US-9056869-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2015-06-16 | — | — | US | disclosed |
| US-9045489-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2015-06-02 | — | — | US | disclosed |
| US-20130096146-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2013-04-18 | — | — | US | disclosed |
| US-8309564-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110295002-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2011-12-01 | — | — | US | disclosed |
| US-20110288108-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | GANGJEE ALEEM (US) | 2011-11-24 | — | — | US | disclosed |
| US-7982035-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2011-07-19 | — | — | US | disclosed |
| EP-2310014-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | Duquesne University of the Holy Ghost (US) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010006032-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2010-01-14 | — | — | WO | disclosed |
| US-20090082374-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082374-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | ABCG2, ABCC1, ABCB1 | MAPT 1383/4885PNP 382/4885CYP3A4 879/4885 |
| US-20200017521-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | PLK1, AURKC, TOP1 | MAPT 2086/4885PNP 1159/4885CYP3A4 2618/4885 |
| US-20110288108-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | ABCG2, ABCC1, ABCB1 | MAPT 1383/4885PNP 382/4885CYP3A4 879/4885 |
| US-10676483-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | PLK1, AURKC, TOP1 | MAPT 2086/4885PNP 1159/4885CYP3A4 2618/4885 |
| US-20180127434-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHOD OF USE THEREOF | ABCG2, ABCC1, ABCB1 | MAPT 1338/4885PNP 327/4885CYP3A4 683/4885 |
| US-20130096146-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | ABCG2, ABCC1, ABCB1 | MAPT 1383/4885PNP 382/4885CYP3A4 879/4885 |
| US-11091500-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | ABCC1, ABCB1, ABCG2 | MAPT 1967/4885PNP 858/4885CYP3A4 2098/4885 |
| US-10464944-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | ABCC1, ABCG2, TP53 | MAPT 1113/4885PNP 843/4885CYP3A4 1642/4885 |
| US-20110295002-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | ABCG2, ABCC1, ABCB1 | MAPT 1383/4885PNP 382/4885CYP3A4 879/4885 |
| US-20170246170-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | ABCC1, ABCG2, TP53 | MAPT 1113/4885PNP 843/4885CYP3A4 1642/4885 |
| US-10414777-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and method of use thereof | ABCG2, ABCC1, ABCB1 | MAPT 1338/4885PNP 327/4885CYP3A4 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.